For EGFR targeting, Yang et al. (2025) created ~90 nm nanomicelles by linking ZEGFR:1907 Affibody with MMAE, achieving an extended half-life (~2.14 h) over monomers (<0.5 h), 4.2-fold greater tumor accumulation in EGFR-positive (A431) models at 8 h, and 97.3% tumor inhibition rate [44]. The gene discussed is EGFR; the disease is neoplasm.